Workboat Indexes
Articles published by Biophytis
Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million
June 30, 2022
From Biophytis
Via AccessWire
Topics
Bonds
Exposures
Debt Markets
Tickers
BPTS
Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives
April 07, 2022
From Biophytis
Via AccessWire
Topics
Initial Public Offering
Tickers
BPTS
Biophytis will Participate in a Key Workshop on Functional Limitations for the Elderly
March 16, 2022
From Biophytis
Via AccessWire
Exposures
COVID-19
Tickers
BPTS
Biophytis Received Approval from ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients through an Expanded Access Program
February 03, 2022
From Biophytis
Via AccessWire
Exposures
COVID-19
Tickers
BPTS
Biophytis Announces the Drawing of the Last Tranche of ORNANE Under the 2020 Atlas Contract for €3 Million
December 22, 2021
From Biophytis
Via AccessWire
Topics
Bonds
Exposures
Debt Markets
Tickers
BPTS
Biophytis to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3
December 16, 2021
From Biophytis
Via AccessWire
Tickers
BPTS
Biophytis Obtains a New 10M€ Loan Structure With Kreos Capital
November 22, 2021
From Biophytis
Via AccessWire
Tickers
BPTS
Biophytis Announces US Centers to Restart Recruitment for the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19
November 15, 2021
From Biophytis
Via AccessWire
Topics
Regulatory Compliance
Tickers
BPTS
Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021
October 29, 2021
From Biophytis
Via AccessWire
Tickers
BPTS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.